IP Library Granted Patent US 7,135,162
Granted Patent B2
US 7,135,162 · App. 10/174,823 · Granted Nov 14, 2006

Agent for diagnosing and treating malignant tumors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,135,162
App. No.
10/174,823
Granted
Nov 14, 2006
Kind
B2
Abstract

A composition of a compound or derivative thereof in which at least one carbon atom of 5-aminolevulinic acid is a carbon isotope and/or a nitrogen atom in its amino group is a nitrogen isotope, and where said derivative is an ester, amide, salt, hydrate or solvate of the compound, and a diagnostically acceptable carrier. A method for detecting malignant tumors, by administering a tumor detecting effective amount to a host in need of tumor detection of a compound or derivative thereof in which at least one carbon atom of 5-aminolevulinic acid is a carbon isotope and/or a nitrogen atom in its amino group is a nitrogen isotope, and where said derivative is an ester, amide, salt, hydrate or solvate of said compound and detecting the malignant tumors using NMR.

Claims (14)

1. A method for detecting malignant tumors, which method comprises administering a tumor detecting effective amount, to a host in need of malignant tumor detection, of 5-aminolevulinic acid or a derivative thereof in which at least one carbon atom of said 5-aminolevulinic acid is a carbon isotope and/or a nitrogen atom in its amino group is a nitrogen isotope, and where said derivative is an ester, amide, salt, hydrate or solvate of said 5-aminolevulinic acid; and

detecting the malignant tumors using NMR.

2. The method of claim 1 wherein said 5-aminolevuliic acid or derivative thereof is used in combination with a diagnostically acceptable carrier.

3. The method of claim 1 , wherein the malignant tumors are detected in a living host.

4. The method of claim 1 , wherein the carbon isotope is used and it is the 13 C or 14 C isotope.

5. The method of claim 4 , wherein the carbon isotope is used and it is the 13 C isotope and the NMR is 13 C-NMR.

6. The method of claim 1 , wherein the nitrogen isotope is used and it is the 15 N isotope.

7. The method of claim 1 , wherein said derivative is used and said derivative is the ester.

8. The method of claim 1 , wherein said derivative is used and said derivative is the amide.

9. The method of claim 1 , wherein said derivative is used and said derivative is the salt.

10. The method of claim 1 , wherein said derivative is used and said derivative is the hydrate.

11. The method of claim 1 , wherein said derivative is used and said derivative is the solvate.

12. The method of claim 1 , wherein the detecting is conducted using a total dose of from 10 mg to 10 g per kg of body weight.

13. The method of claim 1 , wherein said malignant tumors exist in a deep region of tissue.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 028444 FRAME 0241. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jul 25, 2012
From: SBI ALAPROMO CO., LTD.
To: SBI PHARMACEUTICALS CO., LTD.
Reel/Frame 028640/0269 →
CHANGE OF NAME Recorded Jun 26, 2012
From: SBI ALAPROMO CO., LTD.
To: SBI PHARMACEUTICAL CO., LTD.
Reel/Frame 028444/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2009
From: COSMO RESEARCH INSTITUTE; COSMO OIL CO., LTD.
To: SBI ALAPROMO CO., LTD.
Reel/Frame 022694/0507 →